| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07c9542186133097bd6bbb7d92393090 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 |
| filingDate |
1999-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2895af7e59c1225abd0ede0f90e23de7 |
| publicationDate |
2000-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0007584-A2 |
| titleOfInvention |
Method of reducing retinal ganglion cell degeneration |
| abstract |
Disclosed is a method of reducing intraocular pressure or retinal ganglion cell death caused by specific reactive oxygen species by delivering carvedilol or a derivative or metabolite thereof having beta-adrenergic antagonist activity or specific reactive oxygen species scavenging activity to the retinal ganglion cells of a subject having or at risk of developing glaucomatous or other optic neuropathy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015200214-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8067405-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005060974-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8003635-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10124008-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7759333-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7754706-B2 |
| priorityDate |
1998-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |